DexCom (XSWX:DXCM) Research & Development: CHF478 Mil (TTM As of Mar. 2026)


XSWX:DXCM DexCom Inc XSWX:DXCM
90 GF Score
Price CHF56.54
GF Value CHF85.31
! 3 Warning Signs
View Full Analysis

What is DexCom Research & Development?

DexCom XSWX:DXCM 90 Research & Development is CHF478 Mil as of Mar. 2026. GuruFocus rates XSWX:DXCM with a GF Score™ of 90/100 and a GF Value™ of CHF85.31. The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. DexCom's Research & Development for the three months ended in Mar. 2026 was CHF114 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was CHF478 Mil.

DexCom  (XSWX:DXCM) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

DexCom Research & Development Related Terms

DexCom Research & Development Historical Data

* Premium members only.

The historical data trend for DexCom's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DexCom Research & Development Chart

DexCom Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 556.47 451.08 437.42 492.52 477.42

DexCom Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 128.30 120.52 125.39 118.10 114.40
XSWX:DXCM
90GF Score
DexCom Inc XSWX:DXCM
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DexCom Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF478 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of CHF478 Mil mean?
DexCom (XSWX:DXCM) has a Research & Development of CHF478 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on DexCom and its competitors.
Is DexCom's Research & Development too high?
DexCom's current Research & Development is CHF478 Mil. Overall, DexCom has a GF Score™ of 90/100, reflecting its overall financial health beyond just this single metric.
How does DexCom's Research & Development compare to GEHC and STE?
DexCom's Research & Development of CHF478 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on DexCom and its competitors. DexCom's current Research & Development is CHF478 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DexCom stock overvalued right now?
DexCom (XSWX:DXCM) has a current Research & Development of CHF478 Mil. The stock's GF Value™ is CHF85.31, compared to a current price of CHF56.54 — trading 33.7% below its estimated fair value. The current Research & Development is CHF478 Mil. DexCom's overall GF Score™ is 90/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For DexCom (XSWX:DXCM), the current Research & Development is CHF478 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is DexCom (XSWX:DXCM) Overvalued in 2026?

Based on GuruFocus' analysis, DexCom stock appears to be undervalued. The current stock price of CHF56.54 is trading 33.7% below its estimated GF Value™ of CHF85.31.

Key valuation signals for XSWX:DXCM:

  • Research & Development: CHF478 Mil
  • GF Value™: CHF85.31 vs. price of CHF56.54 (33.7% below fair value)
  • GF Score™: 90/100 with 3 warning signs

No single metric tells the full story. See the XSWX:DXCM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

DexCom Business Description

Address 6340 Sequence Drive, San Diego, CA, USA, 92121
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
90GF Score

Get the complete analysis for XSWX:DXCM

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF56.54
Price
CHF85.31
GF Value